Beyond Reshoring:
Building the Infrastructure Behind America's Pharmaceutical Future

For decades, the United States relied heavily on overseas pharmaceutical manufacturing to produce many of the medicines and healthcare products Americans depend upon every day. While globalization delivered efficiencies, it also exposed critical vulnerabilities—from drug shortages and supply chain disruptions to increasing concerns over national preparedness and healthcare security.

Those vulnerabilities became impossible to ignore during the COVID-19 pandemic.
Since then, rebuilding America's pharmaceutical manufacturing capacity has become a national priority.

Last year, President Donald Trump issued executive actions and policy directives designed to strengthen domestic pharmaceutical manufacturing, reduce reliance on foreign supply chains, and encourage greater investment in U.S.-based production.

More recently, the Administration reaffirmed those priorities by announcing plans to pursue additional measures—including potential tariffs on imported pharmaceuticals—to further accelerate domestic manufacturing. While the policy tools may continue to evolve, the direction is becoming increasingly clear. The United States is committed to rebuilding not only its pharmaceutical manufacturing base, but also the infrastructure required to support it.

For Callan JMB (NASDAQ: CJMB), those developments are significant—not because they changed the Company's strategy, but because they reinforce one it has been executing for years.

When people think about reshoring pharmaceutical manufacturing, they often picture production facilities. Manufacturing is certainly essential, but manufacturing alone does not create a resilient pharmaceutical supply chain.

Every pharmaceutical manufacturer depends on an extensive operational ecosystem that includes regulatory compliance, quality systems, secure warehousing, cold chain logistics, fulfillment, workforce development, research collaboration, and reliable distribution networks. Without those supporting capabilities, manufacturing cannot efficiently scale.

Over nearly two decades serving healthcare organizations, pharmaceutical companies, and government agencies, Callan JMB has developed expertise in the operational infrastructure that keeps healthcare moving. That experience has provided the Company with a unique perspective on what America's pharmaceutical future will require.

The conclusion was clear. If the United States was serious about rebuilding domestic pharmaceutical manufacturing, it would need more than factories. It would need an ecosystem.

That vision led Callan JMB to assume the development and operational management of the Atlas Complex in Marion, Alabama. The objective was never simply to breathe new life into a historic campus. It was to help create an integrated life sciences ecosystem where pharmaceutical companies, researchers, academic institutions, logistics providers, and healthcare organizations could operate within a collaborative environment designed to accelerate innovation and strengthen the domestic pharmaceutical supply chain.

Atlas is being developed to bring together capabilities that have traditionally existed in separate locations—research, workforce development, logistics, regulatory expertise, warehousing, quality systems, and pharmaceutical operations.

The goal is straightforward: to create an integrated environment that reduces operational complexity, encourages collaboration, strengthens supply chain resilience, supports innovation, and accelerates the development and commercialization of pharmaceutical products. By bringing these capabilities together, Atlas is designed to help organizations move more efficiently from research and development to manufacturing and distribution.

In many respects, Atlas represents the physical extension of what Callan JMB has spent years building through its core business: connecting supply chains, supporting healthcare operations, ensuring regulatory compliance, and delivering the infrastructure that allows critical healthcare organizations to operate with confidence.

An ecosystem is not built through a single announcement. It is built through strategic partnerships that add new capabilities while strengthening the whole. Earlier this year, Walker's Pharmaceuticals announced plans to establish operations at the Atlas Complex, becoming one of the first pharmaceutical companies to commit to the campus.

That announcement represented more than a new company joining Atlas. It demonstrated confidence in the broader vision of creating an environment specifically designed to support pharmaceutical manufacturing and healthcare innovation.

More recently, Callan JMB announced a strategic partnership with Alabama State University to support pharmaceutical manufacturing, workforce development, research, and operational infrastructure. The partnership recognizes that America's pharmaceutical future depends not only on manufacturing capacity, but also on developing the skilled workforce, research capabilities, and operational expertise necessary to sustain long-term industry growth.

Under the agreement, Callan JMB will provide logistics, compliance management, warehousing, facility management, and operational infrastructure supporting the initiative. Management projects that the agreement could generate more than $414 million in revenue over the initial five-year period, while simultaneously strengthening the pharmaceutical ecosystem being developed at Atlas.

Viewed independently, these announcements represent important milestones. Viewed together, they reveal the deliberate execution of a long-term strategy. Walker's Pharmaceuticals brings pharmaceutical manufacturing expertise to the Atlas Complex, while Alabama State University contributes workforce development, research, and academic collaboration. Callan JMB provides the logistics, regulatory compliance, operational infrastructure, and supply chain expertise that connects these capabilities into a cohesive ecosystem.

Together, these partnerships create opportunities that extend far beyond what any single organization could achieve independently, strengthening the overall value of the Atlas Complex and advancing its vision of becoming a nationally significant center for pharmaceutical manufacturing, research, workforce development, logistics, and healthcare innovation. Each announcement is not simply another partnership—it is another step toward a strategy that has been years in the making.

The Atlas strategy was not developed in response to a single administration or policy announcement. It was built on the belief that America's pharmaceutical industry would eventually require stronger domestic manufacturing supported by equally strong operational infrastructure.

Today, federal priorities increasingly emphasize pharmaceutical reshoring, supply chain resilience, domestic manufacturing, workforce development, and healthcare preparedness. Those priorities closely align with the strategy Callan JMB has been executing through both its core operations and its role in developing and managing the Atlas Complex.

In many respects, the federal government's evolving pharmaceutical manufacturing agenda validates a strategic direction the Company began pursuing well before reshoring became a central national policy objective.

Government policy can accelerate change, but lasting transformation depends on execution. Rebuilding America's pharmaceutical industry requires more than new manufacturing facilities; it demands the infrastructure that supports them. Logistics, regulatory compliance, research partnerships, workforce development, cold chain capabilities, and resilient supply chains are all critical components of a successful pharmaceutical ecosystem.

As the United States continues to prioritize domestic production, the organizations capable of connecting these elements will play an increasingly important role in shaping the industry's future. The organizations that successfully connect these critical components will play an increasingly important role in strengthening America's pharmaceutical future. That is where Callan JMB believes it can make a meaningful contribution.

Through its expertise in pharmaceutical logistics, cold chain management, regulatory compliance, warehousing, emergency preparedness, and operational infrastructure—and through its leadership in developing and managing the Atlas Complex ecosystem—the Company is helping create an environment where pharmaceutical innovation and manufacturing can thrive.

The announcements involving Walker's Pharmaceuticals and Alabama State University are not isolated initiatives. They are intentional building blocks within a much broader long-term strategy.

Together, these partnerships represent more than individual announcements—they demonstrate the deliberate execution of a long-term strategy. Each new collaborator adds capabilities that enhance the overall ecosystem, creating greater opportunities for innovation, operational excellence, and strategic growth. As that ecosystem continues to expand, the Atlas Complex is steadily advancing toward its vision of becoming a nationally recognized center supporting pharmaceutical manufacturing, research, workforce development, logistics, and healthcare innovation.

As the United States continues investing in domestic pharmaceutical production, the conversation should extend beyond where medicines are manufactured. It should also focus on the infrastructure that enables manufacturing to succeed.

Callan JMB believes that infrastructure will become one of the defining competitive advantages in the next chapter of America's pharmaceutical industry. As national priorities continue to evolve, the Company remains focused on executing a strategy centered on operational excellence, strategic partnerships, and the infrastructure required to support a more resilient domestic pharmaceutical supply chain.

By helping build the ecosystem behind pharmaceutical manufacturing—not simply participating in it—Callan JMB believes it is positioning itself to contribute to one of the most significant transformations of the U.S. healthcare industry in decades.